cerca CERCA
Lunedì 29 Novembre 2021
Aggiornato: 08:52
Temi caldi

Advanced non small cell lung cancer

European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

DARMSTADT, Germany, Nov. 26, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations. With this validation, the application is complete, and the EMA will now begin the review procedure. 

ora in
Prima pagina
articoli
in Evidenza